Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

1.

Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.

Ballard C, Isaacson S, Mills R, Williams H, Corbett A, Coate B, Pahwa R, Rascol O, Burn DJ.

J Am Med Dir Assoc. 2015 Jul 31. pii: S1525-8610(15)00442-9. doi: 10.1016/j.jamda.2015.06.021. [Epub ahead of print]

PMID:
26239690
2.
3.

Comprehensive treatment of dementia with Lewy bodies.

Boot BP.

Alzheimers Res Ther. 2015 May 29;7(1):45. doi: 10.1186/s13195-015-0128-z. eCollection 2015.

4.

(11)C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand.

Andersen VL, Hansen HD, Herth MM, Dyssegaard A, Knudsen GM, Kristensen JL.

Bioorg Med Chem Lett. 2015 Mar 1;25(5):1053-6. doi: 10.1016/j.bmcl.2015.01.017. Epub 2015 Jan 20.

PMID:
25655720
5.

Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.

Broadstock M, Ballard C, Corbett A.

Expert Rev Clin Pharmacol. 2014 Nov;7(6):779-86. doi: 10.1586/17512433.2014.966814. Epub 2014 Oct 10. Review.

PMID:
25301532
6.

Treating psychosis in movement disorder patients: a review.

Borek LL, Friedman JH.

Expert Opin Pharmacother. 2014 Aug;15(11):1553-64. doi: 10.1517/14656566.2014.918955. Epub 2014 May 20. Review.

PMID:
24846479
7.

On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.

Hacksell U, Burstein ES, McFarland K, Mills RG, Williams H.

Neurochem Res. 2014 Oct;39(10):2008-17. doi: 10.1007/s11064-014-1293-3. Epub 2014 Mar 30. Review.

8.

Treatment of psychosis and dementia in Parkinson's disease.

Goldman JG, Holden S.

Curr Treat Options Neurol. 2014 Mar;16(3):281. doi: 10.1007/s11940-013-0281-2.

9.

Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs.

Meltzer HY, Roth BL.

J Clin Invest. 2013 Dec;123(12):4986-91. doi: 10.1172/JCI70678. Epub 2013 Dec 2. Review.

10.

Parkinson disease: Pimavanserin could be useful for treating psychosis in Parkinson disease.

Kingwell K.

Nat Rev Neurol. 2013 Dec;9(12):658. doi: 10.1038/nrneurol.2013.233. Epub 2013 Nov 19. No abstract available.

PMID:
24247322
11.

Pimavanserin as treatment for Parkinson's disease psychosis.

Fox SH.

Lancet. 2014 Feb 8;383(9916):494-6. doi: 10.1016/S0140-6736(13)62157-1. Epub 2013 Nov 1. No abstract available.

PMID:
24183566
12.

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.

Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C.

Lancet. 2014 Feb 8;383(9916):533-40. doi: 10.1016/S0140-6736(13)62106-6. Epub 2013 Nov 1. Erratum in: Lancet. 2014 Jul 5;384(9937):28.

PMID:
24183563
13.

Pimavanserin for the treatment of Parkinson's disease psychosis.

Friedman JH.

Expert Opin Pharmacother. 2013 Oct;14(14):1969-75. doi: 10.1517/14656566.2013.819345. Review.

PMID:
24016069
14.

Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.

Hubbard D, Hacksell U, McFarland K.

Behav Pharmacol. 2013 Oct;24(7):628-32. doi: 10.1097/FBP.0b013e3283656db6.

PMID:
23969614
15.

Is there room for non-dopaminergic treatment in Parkinson disease?

Lieberman A, Krishnamurthi N.

J Neural Transm. 2013 Feb;120(2):347-8. doi: 10.1007/s00702-012-0946-0. Epub 2012 Dec 16.

PMID:
23242741
16.

Is there room for new non-dopaminergic treatments in Parkinson's disease?

Pilleri M, Koutsikos K, Antonini A.

J Neural Transm. 2013 Feb;120(2):349-52. doi: 10.1007/s00702-012-0947-z. Epub 2012 Dec 11.

PMID:
23229903
17.

Inverse agonism and its therapeutic significance.

Khilnani G, Khilnani AK.

Indian J Pharmacol. 2011 Sep;43(5):492-501. doi: 10.4103/0253-7613.84947.

18.

Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.

McFarland K, Price DL, Bonhaus DW.

Behav Pharmacol. 2011 Oct;22(7):681-92. doi: 10.1097/FBP.0b013e32834aff98.

PMID:
21921840
19.

Parkinson's disease dementia.

Docherty MJ, Burn DJ.

Curr Neurol Neurosci Rep. 2010 Jul;10(4):292-8. doi: 10.1007/s11910-010-0113-7. Review.

PMID:
20428976
20.

Hallucinations and psychosis in Parkinson's disease.

Rabey JM.

Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S105-10. doi: 10.1016/S1353-8020(09)70846-6. Review.

PMID:
20123547
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk